Mark G. Kris, MD, FASCO provides insight on monitoring patients with NSCLC and discusses the developing role of ctDNA.
EP. 1: Current Treatment Options for Patients with NSCLC
Mark G. Kris, MD, FASCO shares an overview of existing treatment options for patients with stage I-III non-small cell lung cancer.
EP. 2: Strategies for Monitoring Patients with NSCLC
Practical advice on monitoring options for patients with NSCLC treated with definitive radiation therapy or surgery.
EP. 3: Two Key Uses for ctDNA in the Clinical Setting
Dr. Mark Kris shares insight on ctDNA and its use in detecting MRD in NSCLC.
EP. 4: Review of Recent Data on ctDNA From ASCO 2022
A comprehensive review of data presented at ASCO 2022 on ctDNA and MRD detection in NSCLC.
EP. 5: Future Implications of ctDNA in the Management of NSCLC
A thoracic oncology expert provides perspective on ctDNA as a tool and its future as part of the NSCLC landscape.
Dr Liu Previews ASCO 2024 Lung Cancer Data
Dr Rajkumar Previews ASCO 2024 Data in Multiple Myeloma
Ribociclib Plus NSAI Maintains Manageable Safety Profile in HR+/HER2– Early Breast Cancer
Novel CDK4 Inhibitor Shows Activity and Safety in HR+/HER2– Metastatic Breast Cancer